VectorBuilder has partnered with MaxCyte to advance clinical-grade cell engineering. The company is also investing in a biomanufacturing and R&D center and has secured a European patent for its MiniVec plasmid backbone. Additionally, VectorBuilder is advancing its VectorBee software to aid researchers, but the scope and details of these developments are not entirely clear amidst other unrelated announcements in the field of genetic medicine and biotechnology.